Fighting Excessive Pharmaceutical Prices: Evaluating the Options

Exter, André den

doi:10.1163/15718093-bja10004

Cited by 1 publication

(1 citation statement)

References 1 publication

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 Compulsory licenses for anticancer drugs were reported only in Italy, India, and Thailand. 5,9,37 In Thailand, the government issued compulsory licenses for three anticancer drugs (docetaxel, letrozole, and erlotinib) in 2008 to purchase generic drugs from India which resulted in a cost saving of more than US$140 million over 5 years. 9 Compulsory licensing can significantly increase patient access to high-cost drugs, or serve as a negotiating tool to lower manufacturers' drug prices, as seen in Colombia.…”

Section: Use Of Compulsory Licensingmentioning

confidence: 99%

Financing Strategies to Facilitate Access to High-Cost Anticancer Drugs: A Systematic Review of the Literature

Patikorn

Taychakhoonavudh

Sakulbumrungsil

et al. 2021

Int J Health Policy Manag

View full text Add to dashboard Cite

Background: Each country manages access to anticancer drugs differently due to variations in the structure and financing of the health system, but a summary of the various strategies used is absent. This study aimed to review and summarize financing strategies implemented across countries to facilitate access to high-cost anticancer drugs. Methods: We conducted a systematic review of articles referenced in PubMed, Embase, and Web of Science through May 12, 2021. Articles published in the English language from 2000 that describe strategies implemented in different countries to facilitate access to high-cost anticancer drugs were included. Letters, news articles, and proposed strategies were excluded. Quality assessment was not performed as we aimed to summarize the strategies. Data were analyzed by thematic analysis. A review protocol was registered at PROSPERO (CRD42018068616). Results: The review included 204 studies from 176 countries. Three themes of financing strategies were identified: 1) Basic pharmaceutical reimbursement and pricing policies, 2) Alternative funding strategies specific to high-cost drugs, and 3) Financial assistance for individual patients. Access in most countries depends mainly on basic pharmaceutical reimbursement policies (165 of 176 countries). Apart from that, high-income countries tended to use funding strategies targeting high-cost drugs (72% of high-income countries vs 0-24% of the rest), such as Managed Entry Agreements or dedicated funds for high-cost drugs. In contrast, lower-income countries tended to implement financial assistance programs for cancer patients as a tool to increase access (32% of high-income countries vs 62-79% of the rest). Conclusion: Many countries have implemented a combination of strategies to increase access to high-cost anticancer drugs. Most low- and middle-income countries utilized placement of anticancer drugs on a national list of essential medicines and patient assistance programs to facilitate access, while many high-income countries implemented a broader range of strategies.

show abstract